Ocular Therapeutix Inc To Discuss Interim Data Update Call Transcript
Ladies and gentlemen. Thank you for standing by. And welcome to Ocular Therapeutics in term 10-month data update from the ongoing U.S. Phase I clinical trial of OTX-TKI for the treatment of wet AMD. At this time, all participants are in a listen only mode. After the speaker's presentation, there will be a question-and-answer session. (Operator Instructions) Please be advised that today's conference is being recorded. I would now like to hand the conference over to your speaker host Donald Notman, Chief Financial Officer. Please go ahead, sir.
Thank you, Olivia. Good morning, everyone, and thank you for joining us on our conference call to discuss the interim 10 months results from our U.S.-based Phase I clinical trial of OTX-TKI for the treatment of wet AMD. The press release that we issued on Saturday and the slide deck with the interim results can be accessed on the Investors portion of our website at investors.ocutx.com.
Leading the call today will be Anthony Mattessich, our President and Chief Executive
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |